Can SSRIs Prolong the QT Interval?
Yes, SSRIs can prolong the QT interval, but this effect varies significantly by agent—citalopram and escitalopram cause clinically meaningful QT prolongation and carry the highest risk, while other SSRIs (sertraline, paroxetine, fluoxetine, fluvoxamine) cause minimal to no clinically significant prolongation.
Risk Stratification by Specific SSRI Agent
The evidence clearly demonstrates that not all SSRIs are equal regarding cardiac risk 1, 2:
High-Risk SSRIs (Class B*)
- Citalopram: Causes the most significant QT prolongation among SSRIs (+12.8 ms compared to non-use) 3. Associated with dose-dependent increased risk of sudden cardiac death 1. The FDA and EMA have imposed maximum dose restrictions (20 mg for patients >60 years) 1.
- Escitalopram: Second highest risk for QT prolongation 4, 2. Also subject to regulatory dose restrictions 1.
Lower-Risk SSRIs (Class B)
- Sertraline, paroxetine, fluoxetine, fluvoxamine: Meta-analysis shows these cause modest QT prolongation (+6.10 ms overall for the SSRI class), but significantly less than citalopram/escitalopram 4. Paroxetine specifically shows no clinically meaningful QTc prolongation at therapeutic doses (maximum ΔQTcF of +0.42 ms at 60 mg daily) 5.
Clinical Significance and Real-World Outcomes
The pharmacovigilance data reveals important nuances 2:
- Only citalopram (ROR 3.35) and escitalopram (ROR 2.50) show statistically significant signals for QT prolongation in real-world use
- QT prolongation is NOT an SSRI class effect—it is specific to citalopram and escitalopram
However, the clinical translation to serious arrhythmias is complex. A large Danish cohort study found no increased risk of serious arrhythmia with citalopram or escitalopram initiation in older adults (RR 0.87 and 0.85 respectively) 6. Among hemodialysis patients—a particularly vulnerable population—higher QT-prolonging SSRIs (citalopram/escitalopram) showed an 18% increased risk of sudden cardiac death compared to lower-risk SSRIs 7.
Risk Factors That Amplify SSRI-Related QT Prolongation
The following patient characteristics substantially increase arrhythmia risk 1, 7:
- Age >60 years (regulatory dose restrictions apply)
- Female sex (73% of QT prolongation reports) 2
- Renal dysfunction (especially hemodialysis patients) 7
- Cardiac conduction disorders 7
- Electrolyte abnormalities (hypokalemia present in 17% of cases) 2
- Polypharmacy with other QT-prolonging drugs (present in 66% of reported cases) 2
- High doses or recent dose escalation
Practical Management Algorithm
For new SSRI prescriptions:
Avoid citalopram and escitalopram when other SSRIs are suitable alternatives, particularly in high-risk patients
If citalopram/escitalopram are clinically necessary:
- Obtain baseline ECG to measure QTc interval
- Adhere strictly to maximum dose limits (20 mg citalopram in patients >60 years)
- Check electrolytes (potassium, magnesium)
- Review medication list for other QT-prolonging drugs
- Consider follow-up ECG if dose exceeds conservative thresholds or risk factors accumulate
Prefer sertraline, paroxetine, or fluoxetine in patients with:
- Pre-existing cardiac disease
- Multiple QT risk factors
- Polypharmacy with cardiotropic medications
- Renal impairment
For patients already on citalopram/escitalopram: Post-2011 safety warnings appear to have reduced serious arrhythmia risk (RR 0.54 for citalopram) 6, likely due to increased awareness and dose restrictions
Important Caveats
While SSRIs overall increase cardiac arrest risk modestly (OR 1.21) 1, this remains substantially lower than tricyclic antidepressants (OR 1.69, with 7.05 ms greater QTc prolongation than SSRIs) 1, 4. The absolute risk of serious arrhythmia remains low even with higher-risk SSRIs, but the risk-benefit calculation shifts unfavorably when safer alternatives exist within the same drug class.
The Tisdale risk score can reliably stratify QT prolongation risk in hospitalized older adults and should guide medication selection 8.